SCHEMBL30280360

SCHEMBL30280360

COc1ccc(-c2cn(S(=O)(=O)c3ccc(C)cc3)c3ncc(Br)cc23)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 2/20 0.51
KCNH2 Q12809 4/20 0.42
L3MBTL1 Q9Y468 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
USP2 O75604 1/20 0.39
ENPP3 O14638 1/20 0.38
ENPP1 P22413 1/20 0.38
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
KDR P35968 1/20 0.37
TEK Q02763 1/20 0.37
PIK3CA P42336 1/20 0.36
MTOR P42345 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
ACLY P53396 1/20 0.36
PIM1 P11309 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31396616 0.88 PTPN11 (0.53) PTPN11L3MBTL1MEN1KMT2AENPP3
SCHEMBL31396553 0.88 PTPN11 (0.54) PTPN11L3MBTL1MEN1KMT2AENPP3
SCHEMBL31396524 0.86 PTPN11 (0.52) PTPN11L3MBTL1MEN1KMT2AENPP3
SCHEMBL1516664 0.85 PTPN11 (0.52) PTPN11L3MBTL1MEN1KMT2AENPP3
SCHEMBL31396588 0.85 PTPN11 (0.51) PTPN11KCNH2L3MBTL1MEN1KMT2A
SCHEMBL31344454 0.84 PTPN11 (0.50) PTPN11L3MBTL1MEN1KMT2AENPP3
SCHEMBL31396483 0.84 PTPN11 (0.51) PTPN11L3MBTL1MEN1KMT2AENPP3
SCHEMBL30280417 0.84 L3MBTL1 (0.46) PTPN11KCNH2L3MBTL1MEN1KMT2A
SCHEMBL30280495 0.83 PTPN11 (0.45) PTPN11L3MBTL1MEN1KMT2AENPP3
SCHEMBL720190 0.83 PTPN11 (0.49) PTPN11KCNH2L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250019378-A1 PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS HALIA THERAPEUTICS INC (US) 2025-01-16 US disclosed
US-20240425499-A1 TYRO3 INHIBITORS HALIA THERAPEUTICS INC (US) 2024-12-26 US disclosed
WO-2023064218-A1 TYRO3 INHIBITORS Halia Therapeutics, Inc. (US) 2023-04-20 WO disclosed
WO-2023049270-A1 PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS Halia Therapeutics, Inc. (US) 2023-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250019378-A1 PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS TYRO3, TH, TYR PTPN11 65/4885KCNH2 3473/4885L3MBTL1 3734/4885
US-20240425499-A1 TYRO3 INHIBITORS TYRO3, TYR, TH PTPN11 80/4885KCNH2 2638/4885L3MBTL1 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.